AxogenAXGN
Recorded

Axogen Investor update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration1 hr 7 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, everyone, and welcome to AxoGen's Prostate Nerve Reconstruction Investor Event. Joining me on today's call is Michael Dale, AxoGen's President and Chief Executive Officer, Lindsey Hartley, Chief Financial Officer, Jens Kemp, Chief Marketing Officer, and Erick DeVinney, Chief Scientific Officer. We are also pleased to be joined by Dr. David Lee, Professor of Urology at the UC Irvine School of Medicine and Director of the UCI Health Comprehensive Prostate Cancer Program. We will follow with a question-and-answer session. Today's call and presentation is being broadcast live via webcast, which is available on the Investors section of AxoGen's website. Following the end of the live call, a replay will be available on the Investors section of the company's website at www.axogeninc.com.

Operator

Before we begin, please note that today's discussion will include forward-looking statements regarding the potential clinical benefits of nerve reconstruction and protection in radical prostatectomy, our market development plans, and the market opportunity. These statements involve risks and uncertainties that could cause actual results to differ materially, including those described in our most recent Form 10-K, subsequent Forms 10-Q, and other SEC filings. Forward-looking statements speak only as of today, and AxoGen undertakes no obligation to update them, except as required by law. Additionally, guest surgeons are paid consultants to AxoGen Inc. Their statements reflect their personal views and clinical experience. They do not necessarily represent the views of AxoGen, UCI Health, UC Irvine, or any affiliated institution. While the early clinical experience that will be discussed today is encouraging, further evaluation is needed to validate the reproducibility across additional clinical settings. Individual results may vary. Now, I will turn the call over to Michael.

Michael DalePresident and CEO

Michael, please go ahead. Thank you, operator, and good morning, everyone.

Michael DalePresident and CEO

As part of our third quarter earnings release and conference call, we informed the public we had concluded our prospective multicenter clinical experience was positive and that based on the clinical outcomes, we would move forward with market development for the treatment of nerve discontinuities secondary to prostate surgery. Prostate cancer is one of the most common cancers in men, and robotic-assisted radical prostatectomy is considered one of the most effective treatments for localized cancer control. Over the last 20 years, robotic-assisted radical prostatectomy surgery has transformed how these procedures are performed and is widely considered to be standard of care. But for many men, treating the cancer still comes at a significant personal cost, the loss of erectile function, and for some, persistent incontinence. These complications happen because the nerves responsible for these functions run alongside the prostate.

Michael DalePresident and CEO

Based on the extent and location of a person's cancer in the prostate, surgeons, as part of removing the prostate, may be required to also remove some or all of these nerves. Despite advances in robotics and technique, heretofore, there has been no solution for reconnecting these nerves. Offering solutions to nerve discontinuities is precisely the kind of problem AxoGen exists to solve. Our business purpose is to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. We have made significant progress towards that mission in extremities, oral and maxillofacial, head and neck surgery, and breast reconstruction. In prostate, we will apply the same science and commitment to nerve repair best practices to this large and underserved patient population. When we began this program, we set out to answer four questions before committing ourselves to market development. First, clinical need. Is the need real and meaningful to patients?

Michael DalePresident and CEO

Second, market opportunity. Is the market substantial enough to warrant allocating people and capital? Third, surgical execution. Can we develop a reconstruction technique that can be standardized, integrated easily and efficiently into surgical workflow, and scaled in robotic surgery? Fourth, and most importantly, do clinical outcomes demonstrate a positive benefit-to-risk signal? Today, you will hear our answers to these four questions, drawing on our work with 15 nationally and internationally recognized urologists and men's sexual health thought leaders. This collaboration included leading academic centers and surgeons in the U.S. and more than 220 patients who underwent reconstruction with Avance. The early clinical outcomes and experience from this work form the basis of our decision to commence commercial market development for the treatment of nerve discontinuities secondary to prostate surgery. With that, I will turn the call over to Jens.

Jens KempCMO

Thank you, Mike. Every prostatectomy surgeon aims to achieve a clinical trifecta, effective cancer control while preserving continence and erectile function. Our research shows that roughly 60% of the 110,000 prostatectomy cases performed annually are generally nerve-sparing. Of the remaining 40%, roughly half require sacrificing the nerve bundle on one side, and half require wide resection of nerve bundles on both sides. When nerves on both sides are removed, the likelihood of natural recovery is minimal. To understand the impact to patients, we worked with two independent research firms and surveyed more than 450 patients across the prostate cancer journey, including those treated with surgery, radiation, and those on active surveillance. Three findings stood out. First, patients told us quality of life is as important as cancer control, and that changes in erectile function had affected their quality of life.

Jens KempCMO

Most patients said their doctors should do everything possible to preserve or restore erectile function. Second, fear of side effects shapes decisions. 82% of patients told us they avoided or delayed treatment over concern about erectile dysfunction or incontinence. That means the side effects of surgery are not simply a quality of life consideration, it's a barrier to care. We also learned that patients choose prostatectomy primarily for cancer control, and surgery is generally viewed as the most definitive option. Patients choose alternative treatments or active surveillance out of fear of side effects. Third, and most important for AxoGen, patients told us they would act if presented with a better surgical option. 88% said they would ask their surgeon about nerve reconstruction. Among patients who had already undergone other treatments, such as radiation, many said surgery would be back on the table if nerve reconstruction was available.

Jens KempCMO

Many would switch surgeons or hospitals to access it, and would pay out of pocket if it wasn't covered. In addition to our patient research, we surveyed 100 hospital and urologist administrators to understand adoption potential, especially in a situation with limited commercial coverage. This research confirmed the importance of improving prostatectomy outcomes at the facility level. 84% rated improved erectile functional recovery as very or extremely important, and that a meaningful erectile functional improvement can justify pre-coverage adoption. Large, high-volume hospitals appear particularly receptive, with 83% of large 750-bed hospitals supportive of adoption before coverage. In summary, our market research validates not only the unmet need, but the potential market response to our nerve reconstruction technique. Patients want better options, surgeons want better solutions, and many hospitals are willing to adopt in a pre-coverage environment when meaningful clinical benefit can be demonstrated.

Jens KempCMO

Our market research also validated the number of potential procedures, the distribution between nerve-sparing versus non-nerve-sparing procedures, and confirmed our estimated $754 million TAM opportunity. With that, I'll turn it over to Erick.

Erick DeVinneyChief Scientific Officer

Thank you, Jens. That data clearly establishes the need. I'll address the next two questions. Can the procedure be done reliably and at scale? And most importantly, does it help the patients? We approached this the way we approach all nerve repair. Start with the anatomy, apply nerve repair best practices, and partner with leading surgeons in the field to integrate our technology into patient care. Over the past 20 months, we've worked with urologists and sexual health experts to refine the grafting techniques and to follow their early clinical experiences. In addition, we worked with early adopters to evaluate long-term outcomes for recovery of erectile function. As Michael mentioned, the nerves that control erectile function and contribute to continence run along both sides of the prostate. They are often referred to as the neurovascular bundles. Because these nerves are so important, surgeons make every effort to preserve them.

Erick DeVinneyChief Scientific Officer

So why aren't they spared every time? Depending on the location and the severity of the tumor, cancer control may require the surgeon to remove one or both of the bundles along with the prostate. That resection leaves a nerve gap. Based on our experience across the body and other applications, we know that these nerves can regenerate and re-innervate the original target tissue when they have the appropriate path to follow. Avance provides that path, offering a structural scaffold and biological support to bridge the gap. Our first priority was a technique any skilled robotic surgeon could adopt. We learned from the prior work of Davis et al. in 2009, which looked at sural nerve autograft in open prostatectomy procedures, that visualization, identification of the targets, and matching the size of the nerve defect were critical challenges that would need to be addressed.

Erick DeVinneyChief Scientific Officer

There are two key developments that have come a long way since Davis' original work and make this possible now. Robotics provides the visualization and precision that open surgery lacked, and Avance provides an appropriately sized graft to fit the discontinuity without the limitations of small sural nerve autografts. Because we're working within an established robotic workflow, we focused on three technical goals: identifying the tissue structures that contain the nerves, appropriately handling of the graft, and implanting it robotically. In 2015, we completed a technical feasibility study in collaboration with Vanderbilt University. We used those learnings as the foundation to build a technique that allows the robotic urologist to identify the proximal and distal nerve targets and repair those with Avance. We evaluated this technique across a diverse group of surgeons, and we believe this procedure is trainable, reproducible, and scalable.

Erick DeVinneyChief Scientific Officer

A few key additional learnings from this work are that this technique is compatible with multi-port and single-port systems, and it does not require the latest generation robot. It fits well into the robotics workflow, and surgeons estimate it adds under 10 minutes to the overall procedure time. Manuscripts describing this technique have been submitted for publication. Turning to outcomes. More than 220 patients have been reconstructed with Avance to date across the 15 clinical experience sites. Within our surgeon experience study, 117 patients have at least six months of follow-up, 86 grafted on one side and 31 grafted on both sides. Surgeons reported that at six months, approximately 80% of the patients had better-than-expected erectile function, and continence recovery was reported in more than 95% of patients.

Erick DeVinneyChief Scientific Officer

Erectile function was assessed using SHIM, a validated erectile function questionnaire, and continence was evaluated based on pad usage and pad-free continence rates. To be clear, these are surgeon-reported assessments of their own patients based on their own clinical experience, not controlled trial endpoints. Still, when experienced surgeons independently report similar outcomes as measured upon common endpoints, we believe the clinical signal can be considered a meaningful reflection of the procedure. For a more quantitative view, Dr. Tung Shu at Vanguard Urology in Houston retrospectively analyzed 38 of his patients using SHIM, where a score of 15 or higher generally reflects erection sufficient for sexual activity. Among bilateral patients in his study, more than 60% reached the threshold, versus 13% recovery reported in historical controls without reconstruction. Among unilateral repair patients, approximately 80% recovered erection sufficient for sexual activity, versus the 33%-56% reported in unilateral non-nerve-sparing historical controls.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day